Can p110δ inhibitors work against multiple myeloma? If so, what would the timeline be to making p110δ inhibitors available to patients? On a technical note, how do p110δ and its inhibitors differ from proteasome and its inhibitors?
"A class of drug currently being used to treat leukemia has the unexpected side-effect of boosting immune responses against many different cancers, reports a new study. The drugs, called p110´ inhibitors, have shown such remarkable efficacy against certain leukemias in recent clinical trials that patients on the placebo were switched to the real drug. Until now, however, they have not been tested in other types of cancer."
http://www.sciencedaily.com/releases/2014/06/140611132034.htm
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
